Detailed Programme – Thursday 3 July <strong>2008</strong>Presenter = {P} · Abstract numbers are shown in bold and square brackets eg [S123]10.00–10.15 [O23] Dutch carcinoma audits over 2005 and 2006: a consistent 40% had no smear whiledetection failures were 25% in 2005 and 29% in 2006{P} F Van Kemenade, MK Casparie10.15–10.30 [O24] Use <strong>of</strong> RNAi in cell lines to generate optimal controls for optimisation <strong>of</strong> antibodiesfor immunohistochemical analysis on formalin-fixed paraffin embedded samples{P} K Savage, S Parry, E Iorns, N Johnson, CJ Lord, A Ashworth, JS Reis-Filho10.30–11.10 COFFEE [SPORTS HALL 1]ORAL COMMUNICATIONSCategories: Technical Advances; Cardiovascular/Pulmonary; Skin11.10–11.25 [O25] 3-Dimensional pathology with virtual slides{P} D Treanor, K Brabazon, D Magee, P Quirke11.25–11.40 [O26] <strong>The</strong> immunohistochemical differentiation between metastatic breast cancer andmalignant pleural mesothelioma{P} GR Powell, WR Roche11.40–11.55 [O27] Immunohistochemical expression <strong>of</strong> CD10 in cutaneous basal and squamous cellcarcinoma{P} H Aiad, H Hanout12.00–13.00 Conference Auditorium 1PATHOLOGICAL SOCIETY OF GREAT BRITAIN & IRELANDANNUAL BUSINESS MEETING(Members will have received an Agenda)12.00–13.30 Conference Auditorium 2RENAL EQA13.00–14.00 Sports Hall 1LUNCH and TRADE EXHIBITION18<strong>Summer</strong> <strong>Meeting</strong> (194 th ) 1–4 July <strong>2008</strong> Scientific Programme
Detailed Programme – Thursday 3 July <strong>2008</strong>Presenter = {P} · Abstract numbers are shown in bold and square brackets eg [S123]13.30–14.30 Sports Hall 1POSTER VIEWING and CHAIRMAN’S ROUNDSCATEGORIESAutopsy & Forensic [P120–P125] 1Breast (2) [P23–P44] 2Cardiovascular/Pulmonary [P126–P129] 1Cellular/Molecular [P130–P139] 3Education & Audit[P140–P156] 1 (Note: P150 and P153 withdrawn)Endocrine [P157] 4Experimental Tumour Path [P158–P161] 3Gastrointestinal (2) [P60–P74] 5Head & Neck [P162–P164] 4Hepatobiliary/Pancreas [P165–P167] 5Skin [P168–P172] 4Technical Advances [P173–P178] 3Chair:1 Dr PJ Gallagher, Southampton and Pr<strong>of</strong> SB Lucas, London2 Pr<strong>of</strong> AM Hanby, <strong>Leeds</strong> and Pr<strong>of</strong> RA Walker, Leicester3 Pr<strong>of</strong> M Ilyas, Nottingham and Dr JS Reis-Filho, London4 Dr N Kirkham, Newcastle and Pr<strong>of</strong> KA MacLennan, <strong>Leeds</strong>5 Dr MJ Arends, Cambridge and Pr<strong>of</strong> M Pignatelli, Bristol14.30–17.00 Conference Auditorium 1ORAL COMMUNICATIONSCategories: Lymphoreticular; Osteoarticular/S<strong>of</strong>t TissueChair: Pr<strong>of</strong> KA MacLennan, St James’s Institute <strong>of</strong> Oncology, <strong>Leeds</strong>Pr<strong>of</strong> F van Kemenade, VU University Medical Centre, Amsterdam14.30–14.45 [O28] Genomic analysis <strong>of</strong> follicular lymphoma subgroups{P} D Marjenberg, PJ Batstone, KE Robertson, DA Levison, JR Goodlad14.45–15.00 [O29] Genomic instability <strong>of</strong> haemopoietic cells in newly diagnosed MyelodysplasticSyndrome (MDS) and Acute Myeloid Leukemia (AML) assessed by G-banding,multicolour FISH and array-CGH{P} M Yusuf, N Rooney, A Whiteway, T Davies, M Williams, N Affara, R Furlong,P Case15.00–15.15 [O30] PI3K/AKT/mTOR pathway implicated in pathogenesis <strong>of</strong> non-skull basedchordomas{P} A Shalaby, N Presneau, B Idowu, L Thompson, AM Flanagan15.15–15.30 [O31] Activating Gs(alpha) mutational analysis can be used as a diagnostic tool forIntramuscular Myxomas (IM){P} D Delaney, N Presneau, S Hing, BD Idowu, R Tirabosco, AM Flanagan15.30–16.10 TEA [SPORTS HALL 1]<strong>Summer</strong> <strong>Meeting</strong> (194 th ) 1–4 July <strong>2008</strong> Scientific Programme19